Ferguson Wellman Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Ferguson Wellman Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-83,708	Closed	-$3.85M	–	349
2016 Q3	$3.85M	Sell	83,708 -72	-0.1%	-$3.76K	0.16%	116
2016 Q2	$4.21M	Sell	83,780 -59,307	-41%	-$3.16M	0.18%	117
2016 Q1	$7.66M	Buy	143,087 +2,220	+2%	+$130K	0.33%	90
2015 Q4	$9.25M	Buy	140,867 +8,646	+7%	+$534K	0.38%	83
2015 Q3	$7.46M	Buy	+132,221	New	+$8.57M	0.33%	89

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Ferguson Wellman Capital Management's TEVA Position: Q4 2016 in Review

Ferguson Wellman Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 83,708 shares — an estimated $3.85M sold.

Ferguson Wellman Capital Management first reported a position in TEVA in Q3 2015 and held it in 5 quarters. The position peaked at $9.25M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Ferguson Wellman Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Ferguson Wellman Capital Management sold 83,708 Teva Pharmaceuticals shares in Q4 2016, an estimated $3.85M.
Ferguson Wellman Capital Management first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Ferguson Wellman Capital Management's Teva Pharmaceuticals position peaked at $9.25M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Ferguson Wellman Capital Management's 13F filing for Q4 2016, filed 1 Feb 2017.